Celebrex History - Celecoxib History

05/29/2004, Celebrex appears to have lower risk of congestive heart failure, according to Canadian study.

03/02/2002, An overview of the similarities and differences between the popular COX-2 inhibitors prescribed for the treatment of arthritis.

05/14/2001, study compares Celebrex and Vioxx and their cardiovascular side effects.

02/08/2001, FDA Arthritis Advisory Committee met to review study results and to assess if either Celebrex or Vioxx should have warnings on their label reduced or any changes made to the prescribing information.

06/22/2000, Pharmacia and Merck, the respective makers of Celebrex and Vioxx, both reported study results which claim their drug is the better choice for the treatment of osteoarthritis.

02/16/2000, Study results show that Celebrex does not interfere with normal platelet function.

05/09/1999, Follow-up analysis indicates concern over Celebrex report was overblown.

04/21/1999, Reports in the news about Celebrex cause concern, the FDA stresses no need for alarm.

01/13/1999, Manufacturers of Celebrex and Vioxx are competing for the majority of the market trying out the new COX-2 inhibitors.

01/03/1999, FDA approves Celebrex (celecoxib) for osteoarthritis and rheumatoid arthritis.

12/02/1998, FDA advisory panel unanimously recommends the approval of Celebrex for osteoarthritis and rheumatoid arthritis.

06/23/1998, A new class of drugs, COX-2 inhibitors, is being developed which will strengthen the arsenal used to treat arthritis.